ADMA Biologics Inc
ADMA
NASDAQ
Biotechnology
$9.47
USD
+0.06 (+0.64%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.19B
Volume 1.3M
Revenue
$512.27M
TTM
+8.0%
YoY
Gross Margin
65%
TTM
+22.1%
YoY
Net Income
$168.96M
TTM
-19.1%
YoY
Operating Cash Flow
$136.72M
TTM
+78.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 122.0 | 134.2 | 139.2 | 114.5 | 124.4 |
YoY Growth | +13.8% | +12.0% | +18.4% | -0.3% | +2.0% |
Cost of Revenue | 54.8 | 58.6 | 50.3 | 33.7 | 38.1 |
Gross Profit | 67.2 | 75.6 | 88.8 | 80.8 | 86.3 |
Selling, General & Administrative | 22.2 | 21.8 | 23.5 | 26.7 | 26.7 |
Other Operating Expenses | 1.2 | 1.3 | 1.1 | 1.1 | 1.0 |
Total Operating Expenses | 24.4 | 24.6 | 26.1 | 30.5 | 33.8 |
Operating Income | 42.8 | 51.0 | 62.8 | 50.3 | 52.4 |
EBITDA | 44.9 | 53.0 | 64.8 | 52.1 | 54.2 |
Other Income / Expense | -1.3 | -2.2 | -0.0 | 7.8 | -0.0 |
Total Other Income / Expense | -2.7 | -3.5 | -1.2 | 6.8 | -2.2 |
Income Before Income Taxes | 40.1 | 47.5 | 61.6 | 57.1 | 50.2 |
Income Taxes | 5.9 | 11.1 | 12.2 | 11.8 | 12.4 |
Net Income | 34.2 | 36.4 | 49.4 | 45.3 | 37.8 |
Consolidated Net Income / Loss | 34.2 | 36.4 | 49.4 | 45.3 | 37.8 |
Net Income Attributable to Common Shareholders | 34.2 | 36.4 | 49.4 | 45.3 | 37.8 |
Basic EPS | $0.14 | $0.15 | $0.21 | $0.19 | $0.17 |
Diluted EPS | $0.14 | $0.15 | $0.20 | $0.19 | $0.16 |
Basic Shares Outstanding | 241.5M | 238.6M | 235.3M | 236.1M | 228.2M |
Diluted Shares Outstanding | 248.6M | 244.7M | 241.7M | 240.0M | 230.3M |